CO7400872A2 - Derivados sustituidos de ftalazin-1(2h)-ona - Google Patents

Derivados sustituidos de ftalazin-1(2h)-ona

Info

Publication number
CO7400872A2
CO7400872A2 CO15127891A CO15127891A CO7400872A2 CO 7400872 A2 CO7400872 A2 CO 7400872A2 CO 15127891 A CO15127891 A CO 15127891A CO 15127891 A CO15127891 A CO 15127891A CO 7400872 A2 CO7400872 A2 CO 7400872A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
new
compounds
phthalazin
substituted derivatives
Prior art date
Application number
CO15127891A
Other languages
English (en)
Inventor
Brijesh K Srivastava
Ranjit C Desai
Pankaj R Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7400872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CO7400872A2 publication Critical patent/CO7400872A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula general (I), susestereoisómeros, regioisómeros, formas tautómeras y nuevos compuestos intermediariosque intervienen en su síntesis, sus sales farmacéuticamente aceptables, solvatosfarmacéuticamente aceptables y composiciones farmacéuticas que los contienen. Lapresente invención también se refiere a un proceso de preparación de nuevos compuestosde fórmula general (I), sus estereoisómeros, regioisómeros, sus formas tautoméricas, sussales farmacéuticamente aceptables, solvatos farmacéuticamente aceptables, composicionesfarmacéuticas que los contienen, y nuevos compuestos intermediarios que intervienen en susíntesis
CO15127891A 2012-12-31 2015-06-03 Derivados sustituidos de ftalazin-1(2h)-ona CO7400872A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31

Publications (1)

Publication Number Publication Date
CO7400872A2 true CO7400872A2 (es) 2015-09-30

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15127891A CO7400872A2 (es) 2012-12-31 2015-06-03 Derivados sustituidos de ftalazin-1(2h)-ona

Country Status (30)

Country Link
US (1) US9598418B2 (es)
EP (1) EP2938598B1 (es)
JP (1) JP5930452B2 (es)
KR (1) KR101652654B1 (es)
CN (1) CN104918917A (es)
AP (1) AP2015008439A0 (es)
AR (1) AR094299A1 (es)
AU (1) AU2013368842B2 (es)
BR (1) BR112015012425A2 (es)
CA (1) CA2890309A1 (es)
CL (1) CL2015001655A1 (es)
CO (1) CO7400872A2 (es)
DK (1) DK2938598T3 (es)
EA (1) EA201591239A1 (es)
ES (1) ES2614885T3 (es)
GE (1) GEP201706691B (es)
HK (1) HK1210466A1 (es)
HR (1) HRP20170219T1 (es)
HU (1) HUE030613T2 (es)
IL (1) IL238714A0 (es)
MA (1) MA38080A1 (es)
MX (1) MX2015006780A (es)
NZ (1) NZ708255A (es)
PH (1) PH12015501199A1 (es)
PL (1) PL2938598T3 (es)
PT (1) PT2938598T (es)
SG (1) SG11201503670YA (es)
TW (1) TWI553005B (es)
WO (1) WO2014102817A1 (es)
ZA (1) ZA201503218B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
DK3122750T3 (da) 2014-03-26 2019-11-04 Hoffmann La Roche Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
WO2016187620A2 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Anti-cancer compounds
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
JP6876685B2 (ja) * 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
MA42923A (fr) * 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
WO2017071636A1 (zh) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017101796A1 (zh) * 2015-12-16 2017-06-22 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
EP3475272B1 (en) * 2016-06-24 2023-09-13 The Regents of The University of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
KR102296703B1 (ko) 2017-03-20 2021-09-01 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
EP4148046A1 (en) * 2020-05-08 2023-03-15 Txinno Bioscience Inc. Novel phthalazine derivative having ectonucleotide pyrophosphatase/phosphodiesterase inhibitory activity, and use thereof
WO2022192745A1 (en) * 2021-03-11 2022-09-15 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
EP4370125A1 (en) * 2021-07-16 2024-05-22 Oregon Health and Science University Phthalazinone-based parp-1 inhibitors
WO2023174250A1 (en) * 2022-03-15 2023-09-21 Beigene , Ltd. 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
EA006300B1 (ru) 2000-10-30 2005-10-27 Кудос Фармасеутикалс Лимитед Производные фталазинона
GB2415430B (en) 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005066163A2 (en) 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
WO2006039545A2 (en) 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
ES2361566T3 (es) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
KR101491998B1 (ko) * 2006-12-28 2015-02-10 애브비 인코포레이티드 폴리(ａｄｐ-리보스)폴리머라제 억제제
AU2008256562A1 (en) 2007-05-25 2008-12-04 Astrazeneca Ab Combination of CHK and PARP inhibitors for the treatment of cancers
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
ES2524787T3 (es) * 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2012014221A1 (en) 2010-07-27 2012-02-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
CA2841897A1 (en) 2011-07-13 2013-01-17 Santen Pharmaceutical Co., Ltd. Novel compound having parp inhibitory activity
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
KR101684039B1 (ko) 2011-12-31 2016-12-07 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
NZ630170A (en) 2012-02-09 2016-03-31 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Also Published As

Publication number Publication date
PT2938598T (pt) 2017-02-07
JP2016504347A (ja) 2016-02-12
GEP201706691B (en) 2017-06-26
AU2013368842A1 (en) 2015-05-21
PH12015501199B1 (en) 2015-08-17
WO2014102817A1 (en) 2014-07-03
EP2938598A1 (en) 2015-11-04
US9598418B2 (en) 2017-03-21
CA2890309A1 (en) 2014-07-03
HUE030613T2 (en) 2017-05-29
DK2938598T3 (en) 2017-02-13
KR101652654B1 (ko) 2016-08-30
CN104918917A (zh) 2015-09-16
KR20150091137A (ko) 2015-08-07
ES2614885T3 (es) 2017-06-02
ZA201503218B (en) 2016-01-27
PH12015501199A1 (en) 2015-08-17
TW201441219A (zh) 2014-11-01
HK1210466A1 (en) 2016-04-22
EP2938598B1 (en) 2016-12-21
BR112015012425A2 (pt) 2017-07-11
AP2015008439A0 (en) 2015-05-31
NZ708255A (en) 2016-08-26
US20150291603A1 (en) 2015-10-15
JP5930452B2 (ja) 2016-06-08
EA201591239A1 (ru) 2015-10-30
SG11201503670YA (en) 2015-07-30
AR094299A1 (es) 2015-07-22
IL238714A0 (en) 2015-07-01
PL2938598T3 (pl) 2017-05-31
AU2013368842B2 (en) 2015-11-12
TWI553005B (zh) 2016-10-11
MX2015006780A (es) 2015-08-06
CL2015001655A1 (es) 2015-10-02
MA38080A1 (fr) 2018-02-28
HRP20170219T1 (hr) 2017-04-07

Similar Documents

Publication Publication Date Title
CO7400872A2 (es) Derivados sustituidos de ftalazin-1(2h)-ona
DOP2014000016A (es) Indazoles novedosos inhibidores de janus quinasa
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
CR20140464A (es) Compuestos de heterociclilo
NZ721617A (en) Heterocyclic compounds
UY34888A (es) Inhibidores del virus de la hepatitis c
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CR20110370A (es) Derivados de sulfonamida
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
MY175854A (en) Novel quinolone derivatives
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CR20110279A (es) Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
IN2014CN04530A (es)
GEP20176631B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12016500885A1 (en) Novel heterocyclic compounds
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
ECSP077167A (es) Nuevos compuestos heterociclicos